Latest Breaking News On - Treatment burden - Page 1 : comparemela.com

The treatment burden problem

Learn how the overwhelming complexity of managing chronic conditions is leading to an unsustainable treatment burden for 40% of patients

United statesThomas leeIshani ganguliWashington postHarvard medical schoolPress ganeyBoston based harvard medical schoolChronic conditionsTreatment burdenQuality of lifeMedical adviceMedicare patientsOlder adultsPost acute care

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

51 wet AMD patients with severe disease activity and high treatment burden were randomized to high or low dose 4D-150 or aflibercept control regimen4D-150 was well tolerated with a favorable.

United statesArshadm khananiDavid kirnRobert kimJulian peiKatherine smithCorporate communicationsProgram updatesExchange commissionGlobenewswire incClinical data programEuropean unionClinic researchSierra eye associatesD molecular therapeutics incMolecular therapeutics

4DMT Presents Positive Interim Data from Randomized Phase 2

51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden.

United statesDavid kirnKatherine smithRobert kimJulian peiArshadm khananiClinic research at sierra eye associatesProgram updatesEuropean unionCorporate communicationsClinical data programExchange commissionMolecular therapeuticsChief executive officerChief medicalClinic research

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesJulian peiRobert kimDavid kirnArshadm khananiKatherine smithProgram updatesClinic research at sierra eye associatesCorporate communicationsEuropean unionClinical data programExchange commissionPositive interim dataRandomized phaseFavorable tolerabilityClinical activity

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJulian peiRobert kimArshadm khananiKatherine smithDavid kirnExchange commissionCorporate communicationsEuropean unionClinic research at sierra eye associatesProgram updatesClinical data programMolecular therapeuticsChief executive officerChief medicalClinic research